{
  "ticker": "OLMA",
  "company_name": "Olema Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05508906",
      "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer",
      "start_date": "2022-08-31",
      "completion_date": "2028-01-31",
      "enrollment": 0,
      "sponsor": "Olema Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05266105",
      "title": "A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Breast Cancer",
      "start_date": "2021-12-10",
      "completion_date": "2026-03",
      "enrollment": 0,
      "sponsor": "Olema Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06016738",
      "title": "OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma",
      "start_date": "2023-11-16",
      "completion_date": "2027-09-30",
      "enrollment": 0,
      "sponsor": "Olema Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT07085767",
      "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma",
      "start_date": "2025-11-03",
      "completion_date": "2032-01",
      "enrollment": 0,
      "sponsor": "Olema Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04505826",
      "title": "A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer",
      "start_date": "2020-08-13",
      "completion_date": "2024-07-30",
      "enrollment": 0,
      "sponsor": "Olema Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06784193",
      "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant",
      "start_date": "2024-12-16",
      "completion_date": "2027-08-30",
      "enrollment": 0,
      "sponsor": "Olema Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE1": 3,
      "PHASE3": 2,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 4,
      "ACTIVE_NOT_RECRUITING": 1,
      "COMPLETED": 1
    },
    "active_trials": 5,
    "completed_trials": 1,
    "conditions": [
      "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant",
      "Breast Cancer",
      "Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma",
      "Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma",
      "Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer",
      "Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:36.002498",
    "search_query": "Olema Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Olema+Pharmaceuticals,+Inc."
  }
}